Phenytoin (Epilepsy)

Digestive system anomalies

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S12848
R48434		 Thomas (Phenytoin) (Controls exposed to Lamotrigine, sick), 2021 Gastro-intestinal malformations 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No 0.42 [0.01;21.35] C
excluded (control group) 		0/119   0/50 0 119
ref
S12849
R48444		 Thomas (Phenytoin) (Controls unexposed, sick), 2021 Gastro-intestinal malformations 1st trimester prospective cohort unexposed, sick Adjustment: No 0.95 [0.04;23.54] C 0/119   1/340 1 119
ref
S319
R15725		 Morrow (Phenytoin) (Controls exposed to Lamotrigine, sick), 2006 Gastrointestinal tract defects 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 2.65 [0.27;25.78] C 1/82   3/647 4 82
ref
Total 2 studies 1.88 [0.29;12.03] 5 201
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Thomas (Phenytoin) (Controls unexposed, sick), 2021Thomas, 2021 1 0.95[0.04; 23.54]111933%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Morrow (Phenytoin) (Controls exposed to Lamotrigine, sick), 2006Morrow, 2006 2 2.65[0.27; 25.78]48267%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 1.88[0.29; 12.03]52010.210.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Phenytoin) (Controls unexposed, sick; 2: Phenytoin) (Controls exposed to Lamotrigine, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.88[0.29; 12.03]52010%NAThomas (Phenytoin) (Controls unexposed, sick), 2021 Morrow (Phenytoin) (Controls exposed to Lamotrigine, sick), 2006 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 0.95[0.04; 23.54]1119 -NAThomas (Phenytoin) (Controls unexposed, sick), 2021 1 exposed to other treatment, sickexposed to other treatment, sick 2.65[0.27; 25.78]482 -NAMorrow (Phenytoin) (Controls exposed to Lamotrigine, sick), 2006 1 Tags Adjustment   - No  - No 1.88[0.29; 12.03]52010%NAThomas (Phenytoin) (Controls unexposed, sick), 2021 Morrow (Phenytoin) (Controls exposed to Lamotrigine, sick), 2006 2 All studiesAll studies 1.88[0.29; 12.03]52010%NAThomas (Phenytoin) (Controls unexposed, sick), 2021 Morrow (Phenytoin) (Controls exposed to Lamotrigine, sick), 2006 20.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 12848

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 0.95[0.04; 23.54]1119 -NAThomas (Phenytoin) (Controls unexposed, sick), 2021 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.67[0.23; 11.95]42010%NAThomas (Phenytoin) (Controls exposed to Lamotrigine, sick), 2021 Morrow (Phenytoin) (Controls exposed to Lamotrigine, sick), 2006 20.510.01.0